PPARA and metabolic dysfunction-associated steatotic liver disease: As recent researches revealed more and more key targets involved in NAFLD, a variety of new drugs (PPAR agonists, FXR agonists, ASK inhibitors, etc.)are being explored to treat NAFLD.